Tech Center 1600 • Art Units: 1635
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | Non-Final OA | The Regents of the University of California |
| 17931808 | AAV CAPSID VARIANTS | Final Rejection | California Institute of Technology |
| 17615520 | RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF | Non-Final OA | AMGEN INC. |
| 17845592 | USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18177068 | LIPOPHILIC SIRNA CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Non-Final OA | Vanderbilt University |
| 18114923 | METHODS FOR THE TREATMENT OF LUNG TUMORS | Final Rejection | GRADALIS, INC. |
| 17059692 | MODIFIED NUCLEIC ACID INHIBITING MICRO RNA, AND USE THEREOF | Non-Final OA | Korea University Research and Business Foundation |
| 18186290 | IN VITRO GENETIC DISEASE MODEL CELL AND METHOD FOR PRODUCING THE SAME | Non-Final OA | RICOH COMPANY, LTD. |
| 16966851 | COMPOSITIONS AND METHODS FOR INDUCING TRIPARTITE MOTIF-CONTAINING PROTEIN 16 (TRIM16) SIGNALING | Non-Final OA | University of Washington |
| 17627606 | SIRNA SEQUENCES TARGETING THE EXPRESSION OF HUMAN GENES JAK1 OR JAK3 FOR A THERAPEUTIC USE | Non-Final OA | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 17532756 | METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS | Final Rejection | The University of North Carolina at Chapel Hill |
| 17607837 | MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17435365 | ADENO-ASSOCIATED VIRUSES AND THEIR USES FOR INNER EAR THERAPY | Final Rejection | The Trustees of the University of Pennsylvania |
| 18021901 | DEVELOPMENT OF NOVEL GENE THERAPEUTICS FOR INFLAMMATION-INDUCED BONE LOSS | Final Rejection | University of Massachusetts |
| 17596137 | THERAPEUTIC AGENT FOR CANCER | Non-Final OA | OSAKA UNIVERSITY |
| 17432145 | SYSTEM AND METHOD FOR LIGHT-REGULATED OLIGOMERIZATION AND PHASE SEPARATION OF FOLDED DOMAINS AND RNA GRANULE-ASSOCIATED PROTEIN DOMAINS FOR DRUG- BASED SCREENING APPLICATIONS | Final Rejection | The Trustees of Princeton University |
| 17770433 | MICRORNAS ENRICHED IN MEGAKARYOCYTIC EXTRACELLULAR VESICLES AND USES THEREOF | Final Rejection | NATIONAL SCIENCE FOUNDATION |
| 17616430 | STABLE TARGET-EDITING GUIDE RNA HAVING CHEMICALLY MODIFIED NUCLEIC ACID INTRODUCED THEREINTO | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 18727281 | FOLDING OLIGONUCLEOTIDES | Non-Final OA | RNA MORPH LTD |
| 18001813 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17274966 | METHODS FOR INCREASING FETAL HEMOGLOBIN CONTENT IN EUKARYOTIC CELLS AND USES THEREOF FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Non-Final OA | Fondation Imagine |
| 17609691 | MEDIATORS OF GENE SILENCING | Non-Final OA | Cancer Research Technology Limited |
| 17433975 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | Non-Final OA | EDITAS MEDICINE, INC. |
| 17279542 | 2' FANA MODIFIED FOXP3 ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | Final Rejection | The Children's Hospital of Philadelphia |
| 17426059 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | Non-Final OA | KSQ Therapeutics, Inc. |
| 18276061 | Method for Producing Genetically Engineered Cells | Non-Final OA | Cytosurge AG |
| 17248700 | USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES | Non-Final OA | Scholar Rock, Inc. |
| 17604313 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR, IS A NOVEL SENOLYTIC | Non-Final OA | Buck Institute for Research on Aging |
| 18266210 | THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Non-Final OA | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARMENT OF HEALTH AND HUMAN SERVICES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy